[New treatments for idiopathic juvenile arthritis].
Immunosuppressants, including methotrexate and more recently anti-TNF alpha, anti-IL1 and anti-IL6 receptor, have modified the prognosis of juvenile idiopathic arthritis. Growth hormone was shown to limit growth retardation due to general corticotherapy.
Bader-Meunier
B
B
Service d'Immunologie, d'Hématologie et de Rhumatologie Pédiatriques, Centre de Référence << Arthrites Juvéniles >>, Université Paris Descartes, Hôpital Necker-Enfants-Malades, 149 Rue de Sèvres, 75015 Paris, France. brigitte.bader-meunier@nck.aphp.fr
Quartier
P
P
D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors